Your Health, We Care
The most common (>20%) adverse reactions are diarrhea, rash, stomatitis, vomiting, decreased appetite, paronychia, nausea, musculoskeletal pain, dry skin, fatigue, cough, pruritus, and decreased weight. The most common (≥2%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes, increased amylase, increased lipase, decreased potassium, decreased red blood cells, increased creatinine, decreased magnesium and increased alanine aminotransferase.
from FDA，2023.09
Scan code
Whatsapp
Exkivityimproves patient outcomes by inhibiting specific mutant kinases and blocking the proliferation and migration of tumor cells. Exkivityhas been approved by the United States ···【more】
Article source：Lucius LaosRelease date：2024-08-08Recommended：130
Exkivity effectively inhibits the growth and spread of tumor cells by precisely targeting EGFR exon 20 insertion mutations, providing a new treatment option and hope for patients w···【more】
Article source：Lucius LaosRelease date：2024-08-08Recommended：153
Exkivityis an innovative third-representative dermal growth factor receptor (EGFR) tyrosine kinase inhibitor specifically designed for the treatment of patients with non-small cell···【more】
Article source：Lucius LaosRelease date：2024-08-08Recommended：117
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
